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Levetiracetam (LEV) is effective for treating localisation-related epilepsy, but it is uncertain whether it is effective for treating
idiopathic generalised epilepsy. We compared 12-week baseline and LEV treatment periods for patients with generalised seizure
types—myoclonic, tonic–clonic and absence seizures—who had failed other anticonvulsants. The majority of 55 patients (76%)
had >50% seizure reduction with LEV therapy, 40% became seizure-free; 15% discontinued LEV due to adverse events, mostly
sedation. This is preliminary evidence that LEV is effective for treating idiopathic generalised epilepsy.
© 2003 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.
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INTRODUCTION
Levetiracetam (LEV) is an effective antiepilepsy drug
for treating partial-onset seizures1–3. Since LEV is
currently available to patients outside of study pro-
tocols, it is difficult to perform placebo-controlled
trials for treatment of generalised epilepsy. Reliable
clinical data about efficacy of new antiepileptic drugs
(AEDs) for generalised epilepsy is often derived from
large treatment series in which patients’ seizures
are carefully classified and treatment responses are
compared to standard therapies4. Preliminary re-
ports suggest LEV may be beneficial for treating
juvenile myoclonic epilepsy (JME) in patients who
failed treatment with valproic acid5, 6. LEV also
blocks photic-induced generalised spikes in patients
with photosensitive epilepsy in a dose-dependent
manner7.
We report results from a large treatment series at
three epilepsy centres for patients with frequent idio-
pathic generalised seizures—absence, myoclonic and
tonic–clonic seizures—who began LEV treatment
after failing treatment with valproic acid and other
AEDs.
METHODS
Patients with idiopathic generalised epilepsy from
adult epilepsy clinics at Johns Hopkins University
(Baltimore, USA), Vanderbilt University (Nashville,
USA) and University of Birmingham (UK) received
LEV treatment between 1997 and 2001. Patients
were included if they had at least one seizure (ab-
sence, myoclonic or tonic–clonic8) per month during
a 12-week baseline period and had previously failed
treatment with valproic acid or a minimum of one
other AED. Treatment failure was defined as persis-
tent seizures despite a serum level in the ‘therapeutic
range’. AED doses were nevertheless increased to
maximum tolerated. We did not include patients who
were seizure-free on their AED, but wished to switch
because of adverse effects.
Patients had normal MRIs and EEGs consistent
with idiopathic generalised epilepsy, e.g. generalised
spike-wave or polyspike-wave discharges and normal
waking background. Patients with evidence of symp-
tomatic epilepsy were excluded: those with tonic,
atonic, or atypical absence seizure types, generalised
or focal slowing on EEG or brain MRI abnormalities.
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Seizure frequencies were determined for the
12-week periods prior to and following LEV treat-
ment using diaries. Patients with myoclonic and ab-
sence seizures documented all the seizures they were
aware of. Occasional clusters of seizures that could
not be counted were documented separately. Patients
were treated with LEV 500–4000 mg divided BID as
add-on therapy or were converted to monotherapy.
The primary study endpoints were changes in seizure
frequency, seizure responder rates (>50% seizure
reduction) and LEV discontinuation rate. Patients
with clusters of myoclonic or absence seizures had
changes in frequency of cluster episodes measured.
Patient-reported adverse events were recorded. Sub-
ject demographic data, MRI and EEG results, and
seizure types were collected. Patients were grouped
by generalised epileptic syndromes—childhood ab-
sence epilepsy (CAE), juvenile absence epilepsy
(JAE), JME and epilepsy with tonic–clonic seizures
(ETC)9. ETC included patients with tonic–clonic
seizures on awakening. Patients with unclear gener-
alised syndromes were grouped separately.
RESULTS
Subjects
Demographic and EEG data for included patients
(N = 55) are summarised in Table 1.
Seizure types and epilepsy syndromes
A total of 28 patients (51%) experienced only one
seizure type during baseline and treatment periods.
Table 1: Subject data.
Patient total 55
Gender, M/F 21/34
Age, years, mean (range) 30.2 (16–67)
Age at seizure onset, years, mean (range) 11.7 (1–47)
EEG results
Generalised spike-and-wave (SW) 38
Generalised polyspike-and-wave (PSW) 2
Generalised SW and PSW 7
Normal 8
Table 2: Monthly seizure frequency and response classified by seizure type.
Seizure type N Baseline (mean ± SD) LEV treatment (mean ± SD) Percent reduction
Tonic–clonic 43 2.4 ± 2.2 0.9 ± 1.3 62.5
Myoclonic 21 24.7 ± 22.9 3.8 ± 9.0 84.6
Absence 22 32.7 ± 62.7 21.7 ± 63.0 33.6
Overall 55 24.4 ± 46.0 10.8 ± 41.2 55.7
Many patients had multiple seizure types.
The remaining patients had multiple seizure types.
A total of 26 patients (47%) were diagnosed with
JME; 18 patients (33%) had ETC; 11 (20%) had CAE
or JAE. One JME-classified patient experienced only
tonic–clonic seizures during baseline and treatment
periods.
Seven excluded patients had minor features of symp-
tomatic epilepsy (low normal intelligence) or seizure
patterns that were difficult to classify syndromically10;
their treatment responses were assessed separately.
Previous and current AED treatment
Forty patients (72.7%) previously failed treatment
with VPA. A total of 29 patients (53%) previously
failed treatment with three or more AEDs. Failed
previous medications (in order of frequency) were
valproic acid, carbamazepine, phenytoin, lamotrigine
and gabapentin. A majority of patients (73%) were
treated with up to two concomitant AEDs. The re-
maining patients were treated with three concomitant
AEDs (including benzodiazepines).
Seizure response
Mean seizure frequencies and treatment responses
are given in Table 2. Mean baseline monthly seizure
frequencies varied considerably between the three
seizure types: absence seizures 32.7 ± 62.7 SD,
tonic–clonic 0.9 ± 1.3 SD and myoclonic seizures
24.7 ± 22.9 SD. Mean frequencies decreased for all
seizure types during treatment with LEV: myoclonic
seizures 84.6%, tonic–clonic seizures 62.5% and
absence seizures 33.6%.
Response by generalised epilepsy syndromes
Table 3 summarises results by epilepsy syndromes.
Patients with JME had the highest responder rates
to LEV (>50% seizure reduction)—88%, followed
by patients with ETC—78%, and patients with ab-
sence epilepsy—46%. Overall, 42 patients (76.4%)
experienced a 50% or greater decrease in the num-
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Table 3: Levetiracetam response by epilepsy syndrome.
Syndrome Number of Discontinued Responders Seizure
patients due to SE (>50% seizure reduction) free
JME 26 4 (15.3%) 23 (88.4%) 12 (46.2%)
ETC 18 1 (5.6%) 14 (77.8%) 7 (38.9%)
CAE or JAE 11 3 (27.3%) 5 (45.5%) 3 (27.3%)
Overall 55 8 (14.5%) 42 (76.4%) 22 (40%)
ber of seizures during LEV treatment, including 5
who were converted to LEV monotherapy. A total of
22 patients (40%) became seizure-free during treat-
ment with LEV: 12 (46.2%) patients with JME, 7
(38.9%) patients with ETC and 3 (27.3%) patients
with CAE/JAE.
LEV tolerability
Patients tolerated LEV well—21 patients (38%) re-
ported adverse events, none serious. Eight (15%)
patients did not tolerate LEV and discontinued treat-
ment. Adverse events reported by >5% of patients
were (in order of frequency): sedation, nausea and
irritability.
DISCUSSION
Patients with idiopathic generalised seizures had
marked seizure reduction with LEV treatment. A
large number of patients (40%) became seizure-free
or responded to LEV (76.4%) after previously failing
treatment with valproic acid and other anticonvul-
sants. This is preliminary evidence that LEV is bene-
ficial for treating generalised epilepsy. The responder
rates, however, must be viewed cautiously. This is
an uncontrolled treatment series and placebo-effects,
lifestyle changes such as avoidance of sleep depriva-
tion and other treatment factors might have reduced
the frequency of generalised seizures.
Some patients with absence epilepsy did not re-
spond to LEV and one had his first tonic–clonic
seizure during LEV treatment. Most patients with ab-
sence epilepsy with persisting seizures in adulthood,
however, have tonic–clonic seizures. Drug-resistant
absence epilepsy is an unusual syndrome and may not
be representative of patients with more typical child-
hood and JAE syndromes. A small group of patients
had mild cognitive impairment, but otherwise had
features of idiopathic generalised epilepsy. These pa-
tients may represent a spectrum between symptomatic
and idiopathic epilepsy4. Nonetheless, most of these
patients responded to LEV. Most patients were treated
with LEV doses similar to that recommended for
partial-onset epilepsy: 1000–3000 mg/day10.
Our finding that LEV is effective for treating the
generalised epilepsies is consistent with preliminary
reports5–7. There is also strong evidence from animal
studies supporting a possible role for LEV for treat-
ing generalised seizures. LEV has an extremely high
therapeutic index in blocking seizures in the GAERs
absence seizure model11 and blocks startle-induced
generalised seizures in the audiogenic mouse model
of generalised epilepsy12. The effect of LEV and
structural analogues on blocking audiogenic seizures
correlates with binding of the drug to a novel CNS
neuronal receptor that has not been characterised13.
Patients in our series failed treatment with other
AEDs used for generalised epilepsy—valproic acid,
topiramate and lamotrigine—due to adverse events,
poor seizure control, or a combination of both, and
were therefore candidates for treatment with LEV.
The long-term efficacy of LEV for treating gener-
alised epilepsy remains to be determined. There is
preliminary evidence, however, that the drug remains
effective for treating JME for up to 5 years5.
Additional information is needed concerning the
efficacy of LEV for treating generalised epilepsy in
children and for treating severe symptomatic forms
of epilepsy, such as Lennox–Gastaut Syndrome. Our
preliminary findings need to be confirmed in con-
trolled studies, but provide preliminary evidence that
LEV may be effective for treating the generalised
epilepsies in addition to partial-onset epilepsy.
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